DYNE 251
Alternative Names: DYNE-251Latest Information Update: 04 May 2025
At a glance
- Originator Dyne Therapeutics
- Class Antibodies; Antisense oligonucleotides; Drug conjugates; Immunoconjugates
- Mechanism of Action Dystrophin expression stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Duchenne muscular dystrophy
Most Recent Events
- 24 Apr 2025 DYNE 251 receives Orphan Drug status for Duchenne muscular dystrophy in European Union
- 16 Mar 2025 Dyne Therapeutics anticipates a potential Biologics License Application (BLA) submission for US accelerated approval in USA, in early 2026
- 16 Mar 2025 Updated efficacy and safety data from the phase I/II DELIVER trial in Duchenne muscular dystrophy released by Dyne Therapeutics